Quantbot Technologies LP Buys 12,626 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quantbot Technologies LP lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1,870.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,301 shares of the company's stock after purchasing an additional 12,626 shares during the quarter. Quantbot Technologies LP's holdings in IDEXX Laboratories were worth $5,499,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Insight Wealth Strategies LLC lifted its holdings in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares in the last quarter. Larson Financial Group LLC raised its position in IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after buying an additional 2,241 shares during the period. Ontario Teachers Pension Plan Board purchased a new stake in IDEXX Laboratories in the 3rd quarter worth about $749,000. Geode Capital Management LLC boosted its position in IDEXX Laboratories by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock worth $1,138,732,000 after acquiring an additional 40,349 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $1,263,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $533.75.

IDEXX Laboratories Stock Up 0.0 %

Shares of IDXX traded up $0.05 during trading hours on Wednesday, hitting $417.71. 760,713 shares of the company were exchanged, compared to its average volume of 555,046. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $33.86 billion, a PE ratio of 39.15, a PEG ratio of 3.41 and a beta of 1.39. The firm's 50 day moving average is $437.36 and its 200-day moving average is $444.05. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.